CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER: 17-536/S-018 17-536/S-024

CLINICAL PHARMACOLOGY AND BIOPHARMACEUTICS REVIEW(S)

Clinical Pharmacology/Biopharmaceutics Review

Betamethasone dipropionate

NDA 17-536 S-024 (Diprosone Cream 0.05%)

NDA 17-691 S-024 (Diprosone Oint. 0.05%)

NDA 17-781 S-022 (Diprosone Lotion 0.05%)

NDA 19-555 S-016 (Diprolene AF Cream 0.05%)

Reviewer: E.D. Bashaw, Pharm.D.

Schering Corporation Kenilworth, NJ 07033

Submission Date May 31, 2001

Review of Multiple Pediatric Study Reports

Background

These four pediatric supplements are being reviewed together as these supplements are in response to a single pediatric written request. In addition they all relate, ultimately, to a single design in vivo HPA axis suppression study in which all four products were evaluated in the target population (pediatric patients between the age of 3 mos and 12 yrs. with corticosteroid responsive dermatoses).

Study Title: Phase IV multicenter, open label safety studies (four protocols combined) in pediatric patients with atopic dermatitis, treated with betamethasone diproprionate 0.05% formulations (Diprolene AF Cream, Diprosone Ointment, Diprosone Cream, and Diprosone Lotion) twice daily.

Study Design

Although reported out in a single report, this report actually covers four separate studies that utilize similar design features. Specifically the studies were designed to incorporate elements cited in the FDA written request. These can be summarized as follows:

- A minimum of 50 evaluable pediatric patients treated for 2 to 3 weeks with one of the four topical formulations (a total of 200 patients in the four studies);
- 30 of the 50 patients per study in the 6- to 8-year-old age range;
- If there were no rate-limiting safety factors occurring in the 6- to 8-year-old age range, continued enrollment of patients at progressively lower ages until a rate-limiting safety factor was found, or down to the age of 3 months if no safety factor was found;
- Frequent monitoring for cutaneous adverse events, and interruption or discontinuation of study medication for cutaneous adverse events;
- Body surface area with disease involvement of >35%;
- Completion of a 2-week post-treatment follow-up;

• Standard descriptive statistics performed for adverse events, laboratory values, and other safety measures, and a subgroup analysis for use of topical betamethasone dipropionate on the face.

"Rate-limiting safety" factors were defined as the occurrence of at least one of the following:

- Deviation (reduction) of 10% (or greater) from the lower normal limit for serum cortisol and/or an abnormal Cortrosyn® (cosyntropin) challenge response in 10% of patients within any one of the age groups.
- Presence of overt atrophy in 5% (or greater) of patients in any one age group.
- Development of treatment-emergent adverse events of moderate or greater severity in 10% (or greater) of patients in any one age group.
- Presence of any of the individual signs of atrophy of moderate or greater severity in 5% (or greater) of patients in any one age group.
- Presence of striae of any degree in any patient in any one age group.

The trial was designed such that initially 10 patients aged >8 and up to 12 yrs were studied first, followed by 30 patients aged >6 and up to 8yrs, five patients >2 and up to 6yrs, and five patients 3 months up to 2years of age. Prior to going down to the next younger cohort, the results of clinical examination and HPA axis testing was to be completed in the previous cohort. Within a cohort, subset analysis for trends in toxicity were done after each 5 patients completed the trial. Summarized below is the patient age distribution from this trial.

Age Distribution
(planned number of patients per group)

Treatment Group	3mo to 1yr.	2yr to 5yr	6yr to 8yr	9yr to 12yr	Totals
•	(5)	(5)	(30)	(10)	
Diprolene AF Cream	5.	18	30	14	67
Diprosone Ointment	14	28	27	11	80
Diprosone Cream	7	27	20	9	63
Diprosone Lotion	0	0	17	8	25
Totals	26	73	94	42	235

The study population (all treated patients, ITT) age range included 6 months to 12 years. All patients were treated with one of four treatments twice daily for up to 3 weeks. Overall, 114 patients were female, 121 were male, and 111 were caucasian. A total of 196 patients (83%) completed 3 weeks of treatment and completed the 2-week follow-up period.

Cortrosyn® Challenge

HPA axis testing was conducted on day 1, and on either day 14 or 22. This was done so that those patients who cleared at two weeks could complete the trial without having to be exposed to an additional week of unnecessary dosing. Testing was done in accordance to the general directions as contained in the Cortrosyn® package insert. Blood was collected prior to and 30min after administration of 250mcg of Cortrosyn®. The resulting blood samples were analyzed for cortisol and the results are summarized below by formulation, but not by age.

	Baseline				
Treatment Group	Pre-Dose (>5ug/dL)*	30min Post Dose (>18ug/dL)*	Pre-Post Difference (≥7ug/dL)*		
Diprolene AF Cream	51(94%)**	54(100%)	52(96%)		
Diprosone Ointment	59(92%)	57(89%)	56(88%)		
Diprosone Cream	43(96%)	40(89%)	43(96%)		
Diprosone Lotion	13(81%)	13(81%)	13(81%)		

	Day 14					
Treatment Group	Pre-Dose (>5ug/dL)*	30min Post Dose (>18ug/dL)*	Pre-Post Difference (≥7ug/dL)*			
Diprolene AF Cream	50(93%)**	44(81%)	45(83%)			
Diprosone Ointment	60(94%)	49(77%)	49(77%)			
Diprosone Cream	40(87%)	38(83%)	36(78%)			
Diprosone Lotion	12(75%)	5(31%)	7(44%)			

^{*}Criteria for lack of HPA axis suppression

Because of the involved nature of the data, the individual treatment by age group analysis is attached as Tables I-IV.

Examination of the data suggests that all formulations of betamethasone dipropionate can cause some degree of HPA axis suppression. In Study P01260 (Diprolene AF), there was little evidence of clinically relevant HPA-axis suppression based on cortisol response to Cortrosyn® stimulation; however, all four studies were terminated early for rate-limiting safety events associated with abnormal cortisol values. Of particular concern is the lotion product, which shows after a two-week treatment regimen a 69% failure rate to achieve an adequate cortisol stimulation response.

Rate Limiting Safety:

Criteria for rate-limiting safety in four areas (abnormal cortisol levels, adverse events, overt atrophy, and skin atrophy) were met for certain age groups in all four studies. The age groups and categories in which patients met these criteria are as follows:

^{**}Data represents the number of patients and (percentage) with detectable HPA axis suppression

Study P01260 (Diprolene AF Cream) -

abnormal cortisol concentration levels: 2 to 5 years, 6 to 8 years. 9 to 12 years; treatment-emergent adverse events: 2 to 5 years, 9 to 12 years: overt atrophy: 2 to 5 years: signs of skin atrophy: 3 months to 1 year, 2 to 5 years, 9 to 12 years.

Study P01261 (Diprosone Ointment) -

abnormal cortisol concentration levels: 6 to 8 years; treatment emergent adverse events: 3 months to 1 yr, 2 to 5 yts, 6 to 8 yrs, 9 to 12yrs; signs of skin atrophy: 2 to 5 years.

Study P01262 (Diprosone Cream) -

abnormal cortisol concentration levels: 2 to 5 years, 6 to 8 years, 9 to 12 years; treatment-emergent adverse events: 3 months to 1 year; signs of skin atrophy: 6 to 8 years.

Study P01263 (Diprosone Lotion) -

(no patients were enrolled in the 3-month to 1 -year or 2 to 5-year age groups) abnormal cortisol concentration levels: 6 to 8 years, 9 to 12 years; treatment-emergent adverse events: 6 to 8 years

Conclusions

The results of these trials indicate that betamethasone dipropionate is capable of producing the signs and symptoms of corticosteroid related toxicity from any of the four formulations. As a surrogate of in vivo bioavailability the detection of systemic side effects (ie., HPA axis suppression) indicates that pharmacologically significant amounts of corticosteroid are being absorbed.

Recommendations

Based on the wide range of corticosteroid toxicity seen in these patients, across all products and ranges of age, the use of these agents below the age of 12 is not recommended. This recommendation has been forwarded to the reviewing Medical Officer (Dr. Denise Cook) and appropriate labeling will be developed to convey the risk of corticosteroid related adverse events.

Dennis Bashaw, Pharm.D. Team Leader, HFD-540/550/560 PK Review Team

Secondary Review:	Arzu Selen, Ph.D.,	Deputy Director, 1	DPE-III
-------------------	--------------------	--------------------	---------

APPEARS THIS WAY ON ORIGINAL

APPEARS THIS WAY ON ORIGINAL

Detailed Study Synopsis

Title of Study: Phase IV Multicenter, Open-Label Safety Studies (Four Protocols Combined) in Pediatric Patients with Atopic Dermatitis, Treated with Betamethasone Dipropionate (SCH-11460) 0.05% Formulations (Diprolene AF Cream, Diprosone Ointment, Diprosone Cream, and Diprosone Lotion) Twice Daily (Protocols P01260, P01261, P01262. P01263).

Investigator(s): Multicenter: P01 260 (Diprolene AF Cream) - 7 centers

P01 261 (Diprosone Ointment) - 8 centers P01 262 (Diprosone Cream) - 8 centers P01 263 (Diprosone Lotion) - 5 centers

Studied Period: P01 260 - 25 January 2000 to 5 September 2000

P01 261 - 21 January 2000 to 20 October 2000 P01 262 - 17 January 2000 to 7 September 2000 P01 263 - 7 January 2000 to 13 May 2000

Objective(s): To determine the local and systemic safety of betamethasone

dipropionate 0.05% formulations (Diprolene AF cream, Diprosone ointment, Diprosone cream, and Diprosone lotion) when used for the treatment of corticosteroid-responsive dermatoses (atopic dermatitis) in

pediatric patients aged 3 months to 12 years.

Methodology: Multicenter, open-label, safety studies 2 to 3 week treatment with 2 to 4

week follow-up.

Diagnosis and Criteria for Inclusion:

- Patients must have been in the pediatric age group, from 3 months to 12 years of age, of either sex and of any race, and in general good health (non-immunocompromised, ie, immunocompetent).
- A clear diagnosis of atopic dermatitis must have been established, overall disease severity must have been moderate to severe, and total sign/symptom score must have been at least 9.
- Patients must have had disease involving 35% or greater of the body surface area.
- Patients must have demonstrated normal or clinically acceptable morning serum cortisol levels and normal HPA (hypothalamic-pituitary-adrenal) axis responsiveness as determined by a Baseline (pretreatment) Cortrosyn® stimulation test. Results of blood chemistry and hematology tests must have been within normal, or clinically acceptable, limits.

- Patients must not have required any other medication (topical or systemic) that may
 have affected the HPA axis or topical safety, or the course of the disease during the
 study period.
- Patients must not have taken immunosuppressive medication (including systemic steroids) within one month prior to Study Day 1 (day of Baseline evaluations and first day of treatment), and must not have used topical corticosteroids within 7 days prior to enrollment or systemic corticosteroids 28 days prior to enrollment.
- Patients must have been free of chronic diseases (eg, diabetes, renal, hepatic) which could have interfered with interpretation of study results.
- Patients must not have exhibited clinical signs of pre-existing skin atrophy in, or nearby, treatment areas; and must have been free of suspected cutaneous infection of the skin.

Test Product:

The following study medications were applied topically on selected skin areas twice a day for two to three weeks:

Product	Strength	Batch #	Protocol #
Diprolene AF Cream	0.05%		(ProtocolPO1260)
Diprosone Ointment	0.05%		(ProtocolPO1261)
Diprosone Cream	0.05%		(ProtocolPO1262)
Diprosone lotion	0.05%		(Protocol P01263)
Criteria for Evaluat	ion:		

The primary safety endpoints of these studies were the changes in serum cortisol levels in response to Cortrosyn® (cosyntropin) stimulation (HPA axis function), and clinical signs of cutaneous atrophy. HPA axis function was evaluated by assessing levels of serum cortisol prior to and 30 minutes after Cortrosyn® challenge at Baseline (Visit 1, Day 1) and at End of Treatment (Visit 3, Day 15, or Visit 4, Day 22).

Statistical Methods:

Statistical methods include summary/descriptive statistics of baseline and demographic variables, as well as listings and summaries of adverse events, skin atrophy, serum cortisol levels, response to Cortrosyn® testing, and routine laboratory values.

APPEARS THIS WAY ON ORIGINAL

BEST POSSIBLE COPY

President Control of the Control

20 5 PRO ARCH 1 2 2 2 4

Motion and the condition of the following of Consected Mains Center, epon Label Money a Archiver is confused with Assign Second dies.

Expendence will reward the free transfer of the first of the first and the first tenth of the first transfer of , MUTTER

	,		Buse Charge		
Timepolin Forther, Level	formal year	7 (1 - 3 - 5) (1 - 3 - 5)	6 yr - 6 yr (a . 5)	9 yr - 12 yr (n 12)	1 oracl (c. 54)
Bapeline					• ,
<u> </u>		14	29		
Providect manyor"			• •	1.2	5-4
5 1897etti	0 (4 (21	4 (1)	1 (8)	
shipo/dt,	2: (400)	14 (41)	24 6 964	ાં દેવની	3 (F 6) 53 (F9)
Post Cert rosyn ^e + 18 mg/dt					7. (29.1
- 18 401/46.	0 (()	$R_{ij}(k) = P(k)$	0 (0)	ti i e i	0 1 10
Pre/Post Difference	2 (1901	15 (200)	25 (400)	f.: (400)	54 (100)
- / po/di.	U (C)				
 / pq/db 	2 (506)	0 3 04 15 44 00 i	1 4 44	1 (0)	2 3 41
Endpoint		1	24 (90)	41 (1.93)	100
u ·	,:	P _e			
Pre-Cartionys ^a		. ,	4 %	1.2	564
₹+5 pg/db	:	2 1 159	1 (4)	(; e)	
the proposition of the state of	2 (100)	(A. (. a.2)	24 (96)	31 (9.7)	4 (71
Post-Parriceyn ^a			• • •	** * ***	56 (9);
• * 18 ng/d1.	9 (0)	5 (3.5)	4 (16)	1 1 6:	10 (19)
>16 ng/db	3 (160)	10 (67)	21 (84)	14 1 923	44 (811
Pre/Post Difference		•			,, , ,,,,
e 2 pg/df.	1 1 500)	. 1 1 1	5 (20)	1 (6)	9 (17)
% / ng/dL Per Cortiosyn ^h Labeling HPA	1 (50)	11 (07)	20 (80)	11 (921	45 (34)
Axia Suppression at					
Endpoint of	4 (1.50)	6 (40)			
3 Week Follow up		15 3 4123	8 (C)	2 (17)	42 6 110
G	5	•	••		
Pre-Cort rosys ^{a.}	-	•	2:	G	1
≥ 8 pq /db		0 (0)	0 (0)		
ste poplette		£ (190)	2 (100)		9 1 95
Post Cortrowyoff			* (*****		4 11000
- 18 ma/dl.		C + 02	40 (94)		
18 րդ/db _.		2 (1000)	2 (100)		9 4 94 1 1405)
Pro/Post Inflorence			· · · ·		1 111,00
• t_per/itt.		40 (+ +2)	1) (4)		4 ()
• 7 pq/xd1.		2 (100)	2 (100)		F 111.01

[·] Data not avactable or data not applicable.

^{*} Data not available or data not applicable.

Or Total number of subjects with a per Colfrosyn** 86% axis suppression: with a pre Colfrosyn** crimm bution wither set paydhers a post Colfrosyn** cortical value of 8 paydhers a pre/post Colfrosyn** difference of a regist.

Note: 2 week tallow up test was done only if end of treatment test Goty Pr or 22) was absorbed.

Endpoint and of freatment.

Page 1 and 61

College English of the College Englishers Phase IV Mord's Center, Open Label Dimby in Rediater. Confects with Moyor termiting.

Type state stritument: Besterbutton Mumber [3]) of Bullfeet: Based on Response to Sartiesya? Birmalation at Baseline and it Budgerint, By Cathering (Budge is with fire and that Berningen Santiact Valuery (per, it) 08.1000

•	Acte: Group				
Tamby cand Contable: Level	$\frac{\lambda(n)}{(n/\sqrt{12})}\frac{\lambda(n)}{n}$	2 ys - 6 yr (n. 22)	$\frac{\alpha_{i}(y_1) - \mu_{i}(y_2)}{(n/2)!}$	2 yr - 13 yr (n. 10)	701 al (a. 64)
Haneline	See.	•			
\$1	LI	** ** _{\$}	24	1.9	64
Pro Cortrosyn"					
• do payfill.	Ø (# 0)	$6 \cdot 3 = 61$	3 (14)	2 (20)	5 (0)
sta par/ett,	(1 (100)	72 (2001	1H (Ha)	R (8n)	59 (92)
Fort Cort Losyn ^a					F 10 10 10 10 10 10 10 10 10 10 10 10 10
 TR (pq/db) 	0 1 6)	1 (51	4 (19)	2 (20)	2 (11)
st# per/dR,	FT (100)	24 (0.96)	12 (61)	8 (80)	57 (04)
Pre/Post Difficence					, , , , , , , , , , , , , , , , , , ,
$+2$ $\cos/\epsilon \Theta_{\rm c}$	1 (9)	2010 900	4 (19)	1 (10)	0 ((3)
 3 per/ell. 	100 (101)	. 11 1 (1)	1 1 1 11 11	9 (90)	56 (98)
Endpoint				• • • • •	244 7 3444
:1	1.1		.: 1	10	6.4
Tite: Contienyo"			·	•	
soft profitte	1 (9)	1 1 51	1 4 4	1 (10)	4 (6)
√5 payatt.	10 (0.1)	24 1 (0)	20 (95)	0 (90)	60 (94)
best (Cort conyn"				1 - 07	4.0 4 4.44
18 pq/df.	2 (18)	4 1 180	5 (36)	1 2 180	15 6 2 0
<10 pg/dt.	9 (82)	16 (92)	24 1 621	9 (90)	49 (27)
Pre/Pont Difference			2	, , ,,,,	47 1 771
$\pm 2/\log/M_{\star}$	2 (18)	6 (1.27)	6 1 294	1 (10)	
7 pay/dt.	9 (112)	16 (2.0)	15 1 711	9 (90)	15 (23)
Per Cortrollyn ^a Labeling HPA				7 (10)	495 (1.777)
As is Supprentation at			·		
Endport of Ta	4 (36)	9 1 4 ()	14 (1.52)	2 (20)	18.5
2-Week Follow My				2 V AMP	26 (1.44)
11	1		Q	C;	
Pre-Cortionya"		•	••	٠,	7
9 pa/di.	e (9)	30 (1 m)			
(5) μη /cH ₁	i (109)	1 1160)			0 = (-9)
Post Centampys"		• • • • • • • • • • • • • • • • • • • •			2 - (1000)
 DU pay/dl. 	G (3)	0 1 00		•	
528 mg/dt	1 (100)	1 110000	•		0 ((i)
Per/Post Dillerence		2 7,11.113	•		2 (1000)
/ pq/dl.	c (n)	9 (9)			
> Figurett.	1 (100)	1100			0.00000
		* * * * * * * * * * * * * * * * * * * *			2 (10%)

that a nest awar faible or data not applicable.

a: Total number of subjects with a per Corticoyn's HPA axis suppression; with a pre Corticoyn's atreated ren value of pupille or a post Corticoyn's cortisol value of HE pg/dl. or a pre/past Corticoyn's difference of of per/dl. Moter 2 week tollow up test was done only if end of treatment test (bay 15 or 22) was abnormal. Endpoint - end of freatment,

Transport through pres-

2000/02/00 00 00 01

School and Etonolic Research (Egit it des These IV Midtir Center, specifiated Blodg in-Testration Calegoric with Alegare Depart (E.)

Distriction Creams (Markingarian in Mumber (31) of addptin Research Respected to Configuration in Marking and at Radiction, by Calcipary Cautions, with the Sant Part Carticogn" Continued Various, 1992-2003. (BEFF)

			Age Group		
Timeportut gggtugel lævel	1 0at 1 Yt 126 3)	2 yr 3 y (m. 20)	$\frac{6 \cdot y_1 + \widetilde{0} \cdot y_1}{(6 \cdot 150)}$	w yn i da yn In st	Test a 1 (n = 4) t
positi the		·	• •		e de la compe
n ·	•	200	15	7	.1';
Pare Cost a ceryps th					
e. Sometime	9 (0)	F. C. S.F.	6 (0)	1 (14)	2 (4)
Se poperties	1 (100)	19 (95)	(15) (100)	6 (1.06)	4 t (44)
Post Cortroggn"					•
 19 ana/dta 	(i i i; i	1 (5)	3 (13)	2: (-29)	5 (1.11)
+4.8 (16)7/eHz	A 11 OK 1	10 (195)	1 U i 27)	5 (71)	40 (09)
Pre/Post Authoresse					
 7 тка/d4, 	D (€)	G (10)	2 (13)	H + H)	2 1 4)
e 7 popula	A (1300)	76 (109)	43 (87)	7 (196)	4.5 (1.06)
Mindystant					
ti .	3	200	11.	H	4 4.
15 о Соота свун ^е	•				
→ % ner/db	6 (0)	4 (20)	1 (7)	1 (131	6 (13)
	3 (106)	16 (80)	14 (93)	7 (1071)	40 (82)
Prest «Cent gasya"					
3 10 peg/(II)	$\mathbf{O}_{-}(-0)$	4 3 760	1 (20)	F (133)	и (171
19 ma/d1.	* (11000)	16 1 201	12 (00)	7 (88)	19t (10.);
Pre/Pent Difference					
+ 7 ing/dt _e	0 (0)	6 - 1 - 501	4 (27)	. 5 1 03	10 (ap)
⊶* mg/db	1 1100)	14 (70)	11 (1.73)	0 (100)	36 (7R)
Per Cortropyn [®] Labeling HPA					•
Axia Suppleasion of					
Findpoint **	0 (0)	7 (15)	6 (40)	1 (13)	14 (An)
2 Mook Follow up				* * * * *	
1+	n .	3	1	()	· ·
Pro-Cortagoyn"					
s : 5 ng/dL		6 (0)	8 (6)		0 ()
		2 (1) (0)	1 (190)		V (100.4
Prest Coultaopyn*	•		•	•	
7 ± 0 q (q/d);		1 (2.0)	0 (0)		1 (20)
418 vay/dife		1 1 504	1 (100)		
Pre/Post Difference			, , , , , , , , , , , , , , , , , , , ,		2 (37)
A Torridt.		2 11064	0 (5)		
3 pq/db		h (6)	1 (100)		7.1.27
			, ,,,,,,		1 (1.37)

^{*} Cara not available or data not applicable.

^{*} But a not available of state not applicable.

a: Total number of subjects with a per Contronyn'* HPA axis suppression: with a pre Contronyn'*; Cisal dien sales as a middle of a post Contronyn'* cortical value and pg/dL or a pre/pst Contronyn'* difference of a fee/dL.

Hote: 2 week toffew up test was done only if end of treatment test (Bay 15 or 224 was absorbed.) Budpoint - and of treatment.

BEST POSSIBLE COPY

Chemptonic Colorada, Cara-

tooker but it is

 $4 \rightarrow 1$

Befreigner Floren femerale francische There is did a feature, open baket carries in the book are studied by the Atopics Section for the

Sipressum College Distribution (Dister 15) or imberett gave but sempence to contrasys, translation at Baseline and at Freignant, By Category (Subjects with the today). Category, Contrasy, Contrast Values (1937a.) 141111;

Time 1 pt		Age Group				
Board Tree					9 yr 12 yr (m: 5)	
Pre Controsym*	Band Tive	••••	•			•
1						
25 mg/dl.				• • • • • • • • • • • • • • • • • • • •	',	Lú
Post Currency Post Currenc				1 (27)	75 1 103	
10 pg/df.						
11 19/40s 11 10 11 11 11 11 11					, ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	12 (81)
Pro/Pear Dillerouse				1 (27)	(4 1 6	1 (10)
-7 mg/dL 2 (10) 1 (20) 0 (1 10) Endpoint				0 (73)	5 (100)	
Find						,,
Endpoint 9 1 10 1 10 1 10 1 10 10 10 10 10 10 10 1		•		3 ()4)	1 (1 200)	4 (1.19)
Pre Collingsys				9 (933	3 (00)	2 1 1 01)
Pre-Controsys				12		
S pa/db				••	**	16
Post Carterpoynth				4 (27)	1 7 201	4 1 24
### ##################################						
STR pg/dL						• • • • • •
Pre/Post Dillerence 4 1 461 1 (301 6 (41) 7 (44) 7 (44) 4 (401) 9 (501) 7 (44) 8 (40) 1 (20) 7 (44) 8 (40) 1 (20) 7 (44) 8 (40) 1 (20) 7 (44) 8 (40) 1 (20) 7 (44) 8 (40) 1 (20) 7 (44) 8 (40) 1 (20) 7 (44) 8 (40)					4 (80)	14 (40)
Per Voltropyn Labeline 1024 Proposition at Emperior at Emper				4 ()6)	1 (.:01	
### 1970 ### 1970 ### 1970 ### 1970 ### 1970 ### 1970 #### 1970 #### 1970 #### 1970 #### 1970 ##### 1970 ###### 1970 ####################################						
Axis Suppression at Empoint's Axis Suppression at Empoint Axis Suppression at Empoint Axis Suppression						
Embyorit a 2 Meek Follow-up	Per Controllyn ^a Labeting HPA			***************************************	1 6 261	7 (443
### ##################################						
### ##################################				8 1 731	4 + 801	4.9 1 14 4
Pre-Cratiforyall						10 1 (0)
1			•	•,	.:	7
Post Contracych						
Post Cortrosys* - 10 pg/db 14 pg/db 18 pg/db 19 pg/db 19 pg/db 19 pg/db 19 pg/db 19 pg/db 10 pg/db						0.1 (0.2)
- 10 pg/dL				14 (14 (10))	2 (100)	(F160)
**************************************				1 1 203		
Pre/foot Difference 6 1 00 6 10 00 6 1 00 6 1 00 6 1 00 6 1 00 6 1 00 6 1 00 6 1 00 6 1 00 6 10 00 6 1 00 6 1 00 6 1 00 6 1 00 6 1 00 6 1 00 6 1 00 6 1 00 6 10 00 6 1 00 6 1 00 6 1 00 6 1 00 6 1 00 6 1 00 6 1 00 6 1 00 6 10 00 6 1 00 6 1 00 6 1 00 6 1 00 6 1 00 6 1 00 6 1 00 6 1 00 6 10 00 6 1 00 6 1 00 6 10 00 6 1 00 6 10 0						
5. 2 movile 1. 1. 201 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1.	Pre/Post Dillerence			• • • • • • • • • • • • • • • • • • • •	2 (140)	6 (106)
$\sim 2 \cdot \mathrm{rec}/\mathrm{H}$				2 (4.0)	1 1 200	
	5 7 pcj/dl.					

^{*} Bara not available or data not appricable.

^{*} Data and available of data not appricate.

a: Total module of subjects with a per Corticayo^{**} BPA exis suppression: with a pre Corticayo^{**} stampletics with a per Corticayo^{**} corticayo^{**} to be subjected to a perfect Corticayo^{**} cortical value of Copydb or a perfect Corticayo^{**} difference of ** perfola. Note: 2 week follow up test was done only if end-of-treatment tent day 15 m 230 was almoraed, Endpoint a end of treatment.